EFFICACY, DURABILITY AND SAFETY OF FARICIMAB IN DME: 2-YEAR RESULTS FROM YOSEMITE AND RHINE

Miguel Amaro1, Hugh Lin2, Shaun Mohan3, Yannan Tang4, Zdenka Hadova5

1Ophthalmology Department, Hospital Cuf Tejo, Portugal
2Global Product Strategy, Genentech, Inc., USA
3Product Development Safety, Genentech, Inc., USA
4Product Development Data Sciences, Genentech, Inc., USA
5Product Development Clinical Sciences, Genentech, Inc., USA

PURPOSE:
YOSEMITE/RHINE (NCT03622580/NCT03622593) were phase 3 trials that evaluated the efficacy, durability and safety of faricimab, a dual angiopoietin-2/vascular endothelial growth factor A inhibitor, for diabetic macular edema (DME). Year 1 of YOSEMITE/RHINE found that faricimab may extend treatment durability and optimise outcomes for patients with DME. Year 2 aimed to evaluate the longer-term efficacy, durability and safety of faricimab in patients with DME.

METHODS:
Patients were randomised 1:1:1 to faricimab every 8 weeks (Q8W), faricimab according to a personalised treat-and-extend–based regimen (T&E) or aflibercept Q8W (YOSEMITE/RHINE, N = 940/951).

RESULTS:
Mean best-corrected visual acuity gains at 2 years (weeks 92–100) with faricimab Q8W (YOSEMITE/RHINE, +10.7/+10.9 letters) or faricimab T&E (+10.7/+10.1 letters) were comparable to aflibercept Q8W (+11.4/+9.4 letters). At week 96, 62% of the faricimab T&E arm achieved Q16W dosing and 78% achieved ≥ Q12W dosing. Anatomic outcomes (central subfield thickness, absence of fluid) favoured faricimab over aflibercept through year 2. Faricimab was well tolerated, with an acceptable safety profile.

CONCLUSION:
Robust vision gains, anatomic improvements and durability with faricimab up to Q16W were maintained over 2 years.

FINANCIAL DISCLOSURE: Yes